Lung Neuroendocrine Carcinoma — Trials

Lung Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,113 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 389
Recruiting: 206
Ph III recruiting: 27
Growth YoY: −1%
Industry share: 43%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (158)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03890055	Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride	unknown	Phase 4	30	Chifeng Municipal HospitalOTHER	0	Mar 26, 2019	clinicaltrials
NCT02348450	Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer	unknown	Phase 4	308	Guangdong Association of Clinical TrialsOTHER	1	Dec 5, 2016	clinicaltrials